Institutional investors hold a majority ownership of ALXN through the 100.86% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended March 2016, these large investors purchased a net $126.8 thousand shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
CANDRIAM LUXEMBOURG SA Bought 137.4 Thousand shares of Alexion Pharmaceuticals I...